期刊
FUTURE ONCOLOGY
卷 15, 期 7, 页码 705-716出版社
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2018-0594
关键词
EGFR; EGFR inhibitor; epidermal growth factor receptor; IMC-11F8; INSPIRE trial; monoclonal antibody; necitumumab; non-small-cell lung cancer; NSCLC; squamous cell carcinoma; SQUIRE trial; targeted therapy
类别
Personalized patient-precise medicine is being gradually incorporated into clinical practice for the treatment of non-small-cell lung cancer (NSCLC). The EGFR pathway has been explored as a druggable target with monoclonal antibodies such as cetuximab or necitumumab. Necitumumab is a humanized IgG1 anti-EGFR. In the Phase III SQUIRE trial, necitumumab used as first-line therapy in combination with cisplatin and gemcitabine showed a reduction in risk-of-death and a better disease control rate in advanced squamous NSCLC. Thus, necitumumab is now a new first-line treatment option in squamous NSCLC. However, further biomarker research is needed to improve patient selection. Moreover, necitumumab associated with other immunotherapy and targeted agents is currently an important area of research that may yield better outcomes for NSCLC patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据